Skip to content

Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial

Collaborative Care to Alleviate Symptoms and Adjust to Illness in Chronic Heart Failure (CASA) Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01739686
Acronym
CASA
Enrollment
317
Registered
2012-12-03
Start date
2012-08-31
Completion date
2015-12-31
Last updated
2017-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Heart Failure

Keywords

Quality of Life, Symptoms, Palliative care, Symptom management, Disease management, Health delivery

Brief summary

Chronic heart failure is an important public health problem as it is a leading cause of disability, hospitalization, death, and costs. People who live with advanced chronic heart failure suffer from numerous symptoms that affect their daily lives. The investigators are conducting a randomized clinical trial to evaluate a symptom management and psychosocial care intervention to improve health status (symptom burden, functioning, and quality of life). The results will be directly relevant to patients and families who suffer with this illness, as well as to providers, payers, and other researchers.

Interventions

OTHERCASA Intervention

CASA Intervention The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components: A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression. A social worker provides structured counseling targeting adjustment to illness and depression if present. A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. Most of the nurse and social worker visits are by phone.

Sponsors

VA Eastern Colorado Health Care System
CollaboratorFED
University of Colorado, Denver
CollaboratorOTHER
Denver Health Medical Center
CollaboratorOTHER
University of Iowa
CollaboratorOTHER
Denver Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years of age or older * Able to read and understand English * Consistent access to a telephone * Patients have a primary care or other provider who is willing to facilitate intervention medical recommendations * A diagnosis of heart failure with at least one of the following: \[hospitalization primarily for heart failure in the year prior (including current); taking at least 20 mg oral furosemide (or equivalent) daily in a single or divided dose; Brain natriuretic peptide(BNP) ≥ 100 or N-terminal prohormone of brain natriuretic peptide(NT-proBNP) ≥ 500; EF≤40%\] * Report a low health status (KCCQ-SF≤70) * Bothered by at least one target symptom: \[Pain; Depression; Fatigue; Breathlessness\]

Exclusion criteria

* Previous diagnosis of dementia * Active substance abuse or dependence, defined by either a diagnosis of abuse or dependence or an AUDIT-C ≥ 8, or self-reported substance abuse in the past 3 months * Comorbid metastatic cancer * Nursing home resident * Heart Transplant recipient * LVAD recipient

Design outcomes

Primary

MeasureTime frameDescription
Difference in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall score6 monthsThe KCCQ is a self-administered questionnaire that measures heart failure-specific health status. The KCCQ is reliable, sensitive to clinical change, and predicts hospitalization and mortality. The study will test whether there is a difference in KCCQ overall score between the intervention and control groups at 6 months.

Secondary

MeasureTime frameDescription
Difference in symptom distress, measured using the General Symptom Distress Scale6 monthsThe General Symptom Distress Scale (GSDS)includes a measure of overall symptom distress and ability to manage symptoms.
Difference in Self-care of Heart Failure Index (SCHFI)12 monthsThe SCHFI is a valid and reliable 22-item self-report measure of self-care that includes three self-care scales: maintenance, management, and confidence
Difference in Satisfaction with Healthcare6 months
Difference in pain using the PEG6 monthsThe PEG items assess average pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G).
Difference in Patient Health Questionnaire-9 (PHQ-9) score6 monthsThe PHQ-9 is a 9-item valid and reliable instrument that provides a continuous measure of depressive symptoms and is 88% sensitive and specific for a diagnosis of major depressive disorder. The PHQ-9 was developed in medically-ill outpatients, including patients with heart failure.
Change in Dyspnea6 monthsPEG pain measure modified to assess breathlessness
Change in Sheehan Disability Scale12 monthsMeasure of functioning
Change in Quality of Life at the End of Life (QUAL-E)12 monthsThe QUAL-E is a valid and reliable self-report measure of several domains, each scored separately, of quality of life in advanced illness. We will use the relationship with health care system, preparation, life completion, and global quality of life sub-scales.
Change in fatigue using the Patient Reported Outcomes Measurement Information System (PROMIS) fatigue measure6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026